Actelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
Phone+41-61-5656565
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Actelion (VTX:ATLN) Frequently Asked Questions
What is Actelion's stock symbol?
Actelion trades on the VTX under the ticker symbol "ATLN."
Has Actelion been receiving favorable news coverage?
News articles about ATLN stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Actelion earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
What other stocks do shareholders of Actelion own?
Who are Actelion's key executives?
Actelion's management team includes the folowing people:
- Jean-Pierre Garnier Ph.D., Chairman of the Board of Directors (Age 69)
- Jean-Paul Clozel, Chief Executive Officer, Member of the Executive Committee, Delegate of the Board of Directors (Age 62)
- Thomas Widman, Co-Founder
- Andre C. Muller, Chief Financial Officer, Executive Vice President, Member of the Executive Committee (Age 53)
- Otto Schwarz, Chief Operating Officer, Executive Vice President, Member of the Executive Committee (Age 61)
- Guy Braunstein, Executive Vice President, Head of Global Clinical Development, Member of the Executive Committee (Age 60)
- Nicholas Franco, Executive Vice President, Chief Business Development Officer, Member of the Executive Committee (Age 54)
- Martine Clozel, Senior Vice President, Chief Scientific Officer, Head of Drug Discovery, Pharmacology & Preclinical Development, Member of the Extended Actelion Executive Committee (Age 61)
- Marian Borovsky, Senior Vice President, Group General Counsel, Member of the Extended Actelion Executive Committee, Corporate Secretary to the Board of Directors (Age 47)
- Christian Albrich, Senior Vice President, Head Global Human Resources, Member of the Extended Actelion Executive Committee (Age 52)
What is Actelion's official website?
How can I contact Actelion?
Actelion's mailing address is Gewerbestrasse 16, ALLSCHWIL, 4123, Switzerland. The company can be reached via phone at +41-61-5656565.
MarketBeat Community Rating for Actelion (VTX ATLN)
MarketBeat's community ratings are surveys of what our community members think about Actelion and other stocks. Vote "Outperform" if you believe ATLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
